Pharmaceutical

GlaxoSmithKline (GSK) is expanding its campus in Barnard Castle in the United Kingdom with the construction of a $130 million liquid biopharmaceuticals production plant. The 124,000-sf aseptic sterile facility will make injectable liquids for the treatment of respiratory and autoimmune diseases and is slated for completion by November of 2019. Building Information Modeling (BIM) and offsite construction methodologies are being implemented in the delivery of the project, which includes the specification that the building can be replicated anywhere in the world.

Aldevron is building a $30 million plasmid manufacturing facility in Fargo, N.D. The 70,000-sf project will feature 17,000 sf of modular cGMP cleanrooms, as well as ISO 8 processing suites with ISO 7 suites for cell banking and fermentation. The facility will feature airlocked, unidirectional personnel flow within the cGMP production area, single-pass air for all product dispensing and cell banking suites, and integrated facility and environmental monitoring systems.

The International Society for Pharmaceutical Engineering announced the category winners for 2018 ISPE Facility of the Year Awards in March of 2018. The awards include: 

Fraunhofer Institute for Cell Therapy and Immunology opened the Project Centre for Biomedical Engineering and Advanced Manufacturing (BEAM) in March of 2018 in Hamilton, Ontario. Located in the McMaster Innovation Park, the $33 million project involved the renovation and fit-out of an existing warehouse to create a 20,000-sf innovation center offering research, office, and manufacturing space. An additional 20,000 sf on the second floor will house laboratories and offices in the future.

Sanofi Genzyme is expanding its presence in the Framingham Technology Park in Massachusetts where its $80 million, 72,000-sf biomanufacturing facility is currently under construction. A two-story, 14,821-sf addition to the project will enable Sanofi Genzyme to increase its production capacity for advanced therapeutics.

Athenex is planning to break ground by April of 2018 on a pharmaceutical manufacturing facility in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 320,000-sf project will include a 281,000-sf building providing manufacturing, research, office, and warehouse space. Completion is expected in 2019. A second phase of development comprising a 39,000-sf expansion is slated for occupancy in 2020. The general contractor for the project is M+W Group and the estimated cost of construction is $210 million.
 

The Francis Crick Institute (informally known as “the Crick”) is one of the world’s largest dedicated biomedical research centers. Its formal agenda is “to discover the basic biology underlying human health, improving the treatment, diagnosis, and prevention of disease, and generating economic opportunities for the UK.” Achieving this agenda has required some unusual architectural strategies, centered on the notion of “discovery without boundaries”—boundaries between scientific disciplines, institutions, laboratories, and individual researchers—which lies at the heart of the Crick’s culture.

Vetter Pharma began construction in December of 2017 on its United States headquarters in Des Plains, Ill. The $350 million project includes renovation of an existing five-story office building and construction of four new facilities providing over 700,000 sf of pharmaceutical manufacturing and warehousing space. Commercial production is expected to begin at the site by 2022. A second phase of construction comprising two additional buildings will reach completion by 2025. Vetter Pharma is based in Ravensburg, Germany. 

Boehringer Ingelheim began construction in December of 2017 on a 50,000-sf expansion of its 350,000-sf animal vaccine production facility in Athens, Ga. The completed 400,000-sf project will begin commercial operations in mid-2019. Boehringer Ingelheim will also construct a 13,000-sf addition for the manufacture of livestock animal vaccines on its 700,000-sf campus in St. Joseph, Mo.

PharmaForce is planning a $145 million expansion its Ohio pharmaceutical production facilities. A 140,000-sf addition will be constructed on the New Albany campus to accommodate increased manufacturing and warehousing operations, and existing production and warehouse space will be renovated. The Hilliard facility will be renovated and expanded by 1,800 sf to house new manufacturing equipment and supporting infrastructure. Construction will begin in 2018.

The University of Oregon broke ground in March of 2018 on the Phil and Penny Knight Campus for Accelerating Scientific Impact in Eugene. Designed by Ennead Architects and Bora Architects, the first phase of construction will include a $225 million, 160,000-sf facility providing interdisciplinary laboratories for biomedical research, collaboration areas, and public spaces. Completion is expected in early 2020.

Pfizer’s pharmaceutical factory in Dalian, China, has attained LEED-NC Platinum sustainable design certification. The project, which involved a 140,000-sf expansion to accommodate an aseptic workshop for cephalosporin products, began construction in 2014 and reached completion in April of 2017.  As the chosen strategic partner for the project, Johnson Controls was involved throughout the design and construction process and provided building controls systems and lifecycle green building certification consulting services.

Mayo Clinic is partnering with United Therapeutics to build a $41 million lung restoration center in Jacksonville, Fla. Located on Mayo’s Southside campus, the three-story, 75,000-sf facility will support the optimization of lungs destined for transplantation, as well as providing offices, conference rooms, and biomedical research space. Whiting-Turner will begin construction on the project in late 2017 with occupancy expected in spring of 2019. 

Hitachi Chemical Advanced Therapeutics Solutions is expanding its cell and gene therapy manufacturing operations in Allendale, N.J. The project includes construction of a 49,700-sf addition accommodating the Center for Innovation and Engineering, controlled environment rooms, and labs for microbiology, manufacturing development, and quality control. An existing 30,000-sf cleanroom production facility will also be renovated. Completion is expected in mid-2018. 

MilliporeSigma opened its 280,000-sf Life Sciences Center in October of 2017 in Burlington, Mass. Accommodating approximately 100 employees, the facility provides offices and a collaboration center for customers to engage in training, troubleshooting, and experimentation activities. Additionally, a biodevelopment lab enabling small-scale pharmaceutical manufacturers to conduct early-stage clinical trials will open at the site by January of 2018. The Life Sciences Center is located in a five-story leased facility and represents an investment of $115 million.